论文部分内容阅读
美国食品药品监督管理局(FDA)批准了盐酸羟考酮控释片(奥施康定)用于治疗需要服用数天阿片类镇痛药物的中、重度疼痛患者。它适用于需长期服用阿片类药物的初始治疗和随着疼痛强度增强而增加剂量的维持治疗,同时,它可以与各种非阿片类镇痛药和辅助药联用,无需考虑药物之间的相互作用。临床研究结果表明,对中、重度癌痛和非癌性疼痛,如骨关节炎和腰背部疼痛综合征患者,羟考酮控释片具有镇痛疗效。
The U.S. Food and Drug Administration (FDA) approved oxycodone hydrochloride controlled release tablets (OxyContin) for the treatment of moderate to severe pain requiring several days of opioid analgesics. It is suitable for the initial treatment of long-term opioids and maintenance therapy with increasing doses of pain intensity, and it can be used in combination with various non-opioid analgesics and adjuvants without regard to drug interaction. Clinical studies have shown that oxycodone controlled-release tablets have analgesic effects in patients with moderate-to-severe cancer and non-cancerous pains such as osteoarthritis and low back pain syndrome.